Streetbeat News

Products Services

SMR

NuScale Power's stock surged 65% in October, driven by strong investor interest in nuclear energy. The company's innovative small modular reactors (SMRs) have captured market attention, contributing to significant stock gains this year.

Portfolio Pulse from

November 08, 2024 | 3:30 pm

CMCSA

Comcast's potential spinoff of its linear cable networks is unlikely to have a significant impact. The proposal to find a partner for Peacock is intriguing but complicated. ACP losses were lower than expected, aided by new NOW Internet packages, but future broadband losses remain uncertain.

Portfolio Pulse from

November 08, 2024 | 3:30 pm

LCID

Lucid's Q3 results show significant losses and cash burn, with high expectations for the upcoming Gravity SUV launch. Despite potential revenue growth, Lucid's high price to sales ratio makes it an expensive stock compared to peers.

Portfolio Pulse from

November 08, 2024 | 3:30 pm

MYGN

Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. (MYGN) for potential federal securities law violations. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test from January 2025.

Portfolio Pulse from

November 08, 2024 | 3:30 pm

EPAM

EPAM Systems, Inc. has launched StatGPT 2.0, a GenAI application for global economic data, in collaboration with the IMF. This platform is aimed at SDMX sponsor organizations and selected national statistical organizations.

Portfolio Pulse from

November 08, 2024 | 3:15 pm

MRNA

The article discusses two biotech stocks that have made significant breakthroughs, making them attractive investment options this month.

Portfolio Pulse from

November 08, 2024 | 3:15 pm

CMPX

Compass Therapeutics presented new biomarker data related to its CTX-471 clinical activity at the SITC Annual Meeting. This data is part of a Phase 1 trial for CTX-471, an anti-CD137 agonist antibody.

Portfolio Pulse from

November 08, 2024 | 3:15 pm

MDNA

Medicenna presented preclinical data on its innovative cancer therapies, including the anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist programs, at the SITC annual meeting. These therapies are designed to target tumors more effectively by activating in the tumor microenvironment.

Portfolio Pulse from

November 08, 2024 | 3:15 pm

GPRO

GoPro's Q3 earnings and revenues exceeded expectations despite lower unit sales. However, a delayed camera launch could negatively impact revenues in 2024.

Portfolio Pulse from

November 08, 2024 | 3:00 pm

CUK

Princess Cruises is offering a special cruise to celebrate the 250th Anniversary of the United States in 2026. The Sapphire Princess will sail its first-ever season, alongside the return of the Majestic Princess, with three departure ports.

Portfolio Pulse from

November 08, 2024 | 2:45 pm